CHRISTOPHER KROEGER, M.D., M.B.A.
Dr. Kroeger joined OvaScience as Chief Executive Officer in September 2017. He brings more than 20 years of experience leading, building and advising development-stage therapeutic and medical device companies, as well as the expertise of a physician and scientist. Most recently, he served as CEO of Cardioxyl Pharmaceuticals. In this role, Dr. Kroeger led a team that produced three investigational new drug candidates and successfully executed six Phase 1 and Phase 2 clinical studies, culminating in the sale of the company to Bristol Myers Squibb for $2.1 billion in total consideration. Prior to Cardioxyl, he led investing efforts as a Partner at The Aurora Funds, a venture capital firm focused on early stage biotechnology and medical device companies. Earlier in his career, he held positions at Genzyme and Decision Resources.
Dr. Kroeger earned his B.A. from Harvard University and his M.D. from Stanford University School of Medicine. He completed his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School. Dr. Kroeger also holds his M.B.A. from Harvard Business School. He currently serves on the Board of Directors of CardioFocus and Cantex Pharmaceuticals.
RICH ALDRICH, M.B.A.
Mr. Aldrich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Vertex Pharmaceuticals, Sirtris Pharmaceuticals (acquired by GlaxoSmithKline in 2008), Concert Pharmaceuticals (where he serves as Chairman of the Board), and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem, Flex Pharma, and Axial Biotherapeutics, where he is a Director. Mr. Aldrich also serves as a Director of Longwood portfolio companies Mitobridge, Inc., Renovia, Inc., and KalVista Pharmaceuticals. Prior to co-founding Longwood, Mr. Aldrich was General Partner of RA Capital, a life sciences hedge fund he co-founded in 2001 and in which he remains an investor. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen.
Mr. Aldrich earned his B.A. from Boston College and his M.B.A. from the Amos Tuck School at Dartmouth College.
JEFFREY D. CAPELLO, M.B.A., C.P.A.
Mr. Capello is Executive Vice President and Chief Financial Officer of Biogen, and has served on the Executive Committee of the company since December 2017. Mr. Capello joined Biogen from Beacon Health Options, Inc., where he served as Executive Vice President and Chief Financial Officer. Mr. Capello was previously Chief Financial Officer of Ortho Clinical Diagnostics, Boston Scientific Corporation, and Perkin Elmer. His finance experience also includes the founding and running of his own company, Monomoy Advisors. Earlier in his career, Mr. Capello was a partner in the Boston and Amsterdam offices of PricewaterhouseCoopers. He was also a member of the Board of Directors of Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), and served on its Audit Committee as both a member and its chair.
Mr. Capello is a certified public accountant. He holds a B.S. from the University of Vermont and an M.B.A. from Harvard Business School.
Ms. Fisher is Chair, Chief Executive Officer and Director at Colorescience, a former division of SkinMedica Inc., where she served as Chief Executive Officer from 2008 until 2012. She led the successful sale of the company to Allergan for $350 million with the potential for another $25 million contingent on certain sales milestones. Ms. Fisher has more than 30 years of experience in the pharmaceutical and biotechnology industries, including management and leadership positions at Acorda Therapeutics, Cephalon, Immunex and Boehringer Ingelheim. She is on the Board of Directors of MDRejuvena and is a Member of the Women’s Dermatological Society and the Dermatology Foundation Leader’s Society. In 2013, Ms. Fisher was honored as Ernst & Young’s Entrepreneur of the Year for San Diego and also received the EY Venture Capital Award of Excellence.
JOHN HOWE, M.D.
Dr. Howe is a well-recognized expert in international medicine and a humanitarian leader. He is the former President and CEO of Project HOPE, an international health education and humanitarian assistance foundation, which operated more than 70 programs in 45 countries on five continents. Previously, he was the President of the University of Texas Health Science Center at San Antonio, where he held the Distinguished Chair in Health Policy and is now President Emeritus. He is a Board member of Boston University, the Texas Biomedical Research Institute, the Mary Christie Foundation and MAXIMUS Federal. His numerous honors and awards include the Surgeon General’s Service Award, the U.S. Army Commander’s Award for Public Service, the Magnolia Award from the City of Shanghai and honorary degrees from Jefferson University and the University of Massachusetts. He is a published author of numerous articles, chapters and abstracts in peer-reviewed medical journals, including the New England Journal of Medicine and the Annals of Internal Medicine.
Dr. Howe earned his B.A. from Amherst College and his M.D. from the Boston University School of Medicine. He later completed the Health Systems Management Program at the Harvard Business School. Dr. Howe is board certified in both internal medicine and cardiovascular disease.
MARC KOZIN, M.B.A.
Mr. Kozin has over 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. Mr. Kozin served as President of the North American practice of L.E.K. Consulting, a global strategy consulting firm, for 15 years and has been a Senior Advisor to L.E.K. since July 2011. He currently serves as a member of the Board of Directors of UFP Technologies, Flex Pharmaceuticals, Endocyte, and one privately held company. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm.
Mr. Kozin holds a B.A., with distinction, from Duke University and an M.B.A., with distinction, from The Wharton School at the University of Pennsylvania.
JOHN SEXTON, Ph.D., J.D.
Dr. Sexton is President Emeritus of New York University. He served as the fifteenth President of NYU from 2001 until 2015. He is a Fellow of the American Academy of Arts and Sciences, a member of the Council on Foreign Relations, and a past member of the Executive Committee of the Association of American Universities. He previously served as the Chairman of the Board of the Federal Reserve Bank of New York and Chair of the Federal Reserve Systems Council of Chairs. He was awarded the TIAA-CREF Hesburgh Award for Leadership Excellence, the Foreign Policy Association Medal, the NASPA President’s Award for advancing the quality of student life at NYU, and was named one of the “Top Ten College Presidents” by TIME magazine. Earlier in his career at NYU, he was the Dean and Benjamin Butler Professor of Law at NYU School of Law. Prior to NYU, Dr. Sexton was Law Clerk to Chief Justice Warren Burger of the United States Supreme Court and to Judges David Bazelon and Harold Leventhal of the United States Court of Appeals. Additionally, Dr. Sexton served as Special Master Supervising Pretrial Proceedings in the Love Canal Litigation. He also served as Professor of Religion and Department Chair at Saint Francis College. Dr. Sexton is a published author of several books, chapters, articles and Supreme Court briefs.
Dr. Sexton holds a B.A. in History from Fordham College, an M.A. in Comparative Religion and a Ph.D. in History of American Religion from Fordham University, and a J.D. from Harvard Law School.